NCT04964479

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

A Randomized, Blind, Parallel Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Pembrolizumab Injection as a First-line Treatment on Patient With Advanced NSCLC.

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 375 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus K drug as a first-line treatment of advanced non-small cell lung cancer.A total of 375 subjects will be enrolled.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	TQB2450 injection	1200mg injection once every 3 week
DRUG	Anlotinib Hydrochloride Capsules	12mg capsule once daily
DRUG	Pembrolizumab injection	200mg injection once every 3 week
DRUG	Placebo	Placebo capsule once daily

Timeline

• Start date: 2021-08-06
• Primary completion: 2022-12-01
• Completion: 2023-03-01
• First posted: 2021-07-16
• Last updated: 2021-08-20

Locations

17 sites across 1 country: China